Availability & Financial Support DANYELZA® (naxitamab-gqgk)

Availability & financial support

DANYELZA® is now offered at many treatment centers across the United States, and availability is expanding every day

It is possible to get DANYELZA without traveling from your home hospital

However, if you are unable to access DANYELZA at your home hospital, you can use the map below to find the treatment center nearest you that already offers it.*

The treatment centers listed here are only those that have authorized their participation on our website. Please check back regularly as this list will be updated periodically.

Enter a city, state, or ZIP code:

Get Your Directions

LOCATE YOUR GEOPOSITION

Search Location

Stores: 0 PRINT
Loading...

Directions

The contact information for these treatment centers is provided as a courtesy, and it is not intended as an endorsement or recommendation of any healthcare provider/treatment center. Y-mAbs® Therapeutics does not make any representations or guarantees about the qualifications, competence, or skills of any healthcare provider/treatment center, the accuracy of any diagnosis, or the appropriateness of any treatment that a healthcare provider may prescribe or recommend. Patients should make their own, independent decisions regarding the capabilities and suitability of potential healthcare providers/treatment centers, and Y-mAbs does not play a role in any patient-provider relationship you may establish.

For suggestions on how to talk with your child’s doctor about getting DANYELZA, get your personalized Doctor Discussion Guide>

DANYELZA Caregiver, Rachalle

"Sometimes you've got to push a little bit and give a little bit of push because nobody knows your kid like you do. So you just have to advocate for them and follow your instincts as a mom. And you have to do that to get them the appropriate care that they need."

–Rachalle, actual DANYELZA caregiver

Y-mAbs Therapeutics is dedicated to helping qualifying patients access DANYELZA

DANYELZA Y-mAbs ConnectTM Logo

Y-mAbs ConnectTM may provide access and reimbursement assistance for qualifying patients prescribed a Y-mAbs medication

Our dedicated team of Y-mAbs Connect case managers can provide information on:

  • Insurance coverage for DANYELZA
  • Prior authorization and appeals requirements of insurer
  • Y-mAbs Connect financial support programs
  • Other financial or travel support programs provided by third-party organizations*
Email Enrollment Icon

How to enroll

If your child was prescribed DANYELZA, your healthcare provider can complete the Y-mAbs Connect enrollment form with you and return it by fax, mail, or email. A Y-mAbs Connect case manager will contact you once you have been enrolled.
Note: Third-party organizations are not associated with Y-mAbs Therapeutics, Inc.; specific details and eligibility requirements may vary by organization.

For more information and to download the enrollment form, visit ymabsconnect.com>

Financial Support Icon

Financial support may be available

Y-mAbs Connect Co-pay Program†
  • For eligible individuals with commercial or private insurance
  • May help reduce out-of-pocket costs of DANYELZA to $0 for eligible patients
Y-mAbs Connect Patient Assistance Program‡
  • For eligible individuals who are uninsured or are rendered underinsured for DANYELZA through their health plan
  • May be able to provide DANYELZA at no cost
Take the first step!

You must be enrolled in Y-mAbs Connect to access these programs. Please visit ymabsconnect.com or speak to a case manager for additional eligibility criteria and terms and conditions.

You can also speak with a Y-mAbs Connect case manager at 1-833-33YMABS (1-833-339-6227), option 2, Monday through Friday, 8 AM to 8 PM ET.

Third-party organizations are not associated with Y-mAbs Therapeutics, Inc.; specific details and eligibility requirements may vary by organization. ​

Eligibility criteria for the Co-pay Program include but are not limited to patients who have commercial or private insurance, are US or US territory residents, and are actively insured at time of treatment. Government- or publicly insured patients are not eligible.

For the Patient Assistance Program you must meet certain eligibility criteria.

Note: Y-mAbs Therapeutics, Inc. reserves the right at any time, and without notice, to modify or discontinue these programs and any support provided to the patient.

Quick links

Get financial and emotional support
from these community groups ​

Get tips for preparing for
treatment from other caregivers

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about DANYELZA?
DANYELZA may cause serious side effects, including:

Serious infusion-related reactions. DANYELZA can cause serious infusion-related reactions that require immediate medical attention. Infusion-related reactions are common with DANYELZA. Tell your healthcare provider right away if you get any signs or symptoms during or after your DANYELZA infusion, including:

  • swelling of your face, eyes, lips, mouth, or tongue
  • itching
  • redness on your face (flushing)
  • skin rash or hives
  • trouble breathing
  • cough or wheezing
  • noisy high-pitched breathing
  • feeling faint or dizziness (low blood pressure)

WHAT IS DANYELZA?

DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:

  • has come back (relapsed) or that did not respond to previous treatment (refractory), and
  • has shown a partial response, minor response, or stable disease to prior therapy.

DANYELZA is approved based on two clinical studies that looked at reducing tumor size. DANYELZA is still being studied to confirm the study results and the clinical benefit of treatment.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about DANYELZA?
DANYELZA may cause serious side effects, including:

Serious infusion-related reactions. DANYELZA can cause serious infusion-related reactions that require immediate medical attention. Infusion-related reactions are common with DANYELZA. Tell your healthcare provider right away if you get any signs or symptoms during or after your DANYELZA infusion, including:

  • swelling of your face, eyes, lips, mouth, or tongue
  • itching
  • redness on your face (flushing)
  • skin rash or hives
  • trouble breathing
  • cough or wheezing
  • noisy high-pitched breathing
  • feeling faint or dizziness (low blood pressure)

WHAT IS DANYELZA?

DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:

  • has come back (relapsed) or that did not respond to previous treatment (refractory), and
  • has shown a partial response, minor response, or stable disease to prior therapy.

DANYELZA is approved based on two clinical studies that looked at reducing tumor size. DANYELZA is still being studied to confirm the study results and the clinical benefit of treatment.

Nervous system problems. Talk to your healthcare provider right away if you have new symptoms or worsening of nervous system problems, including:

  • Severe pain from nerves (neuropathic pain), including pain in the belly (abdomen), bone, neck, legs, or arms. Pain is common with DANYELZA and can be severe.
  • Inflammation of the spinal cord. Signs or symptoms may include:
    • weakness in your legs or arms
    • bladder and bowel problems
    • pain in back, legs, or stomach (abdomen)
    • numbness
    • tingling
    • burning sensation
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS – also known as Posterior Reversible Encephalopathy Syndrome - PRES). PRES is a condition that affects the brain. Your healthcare provider will monitor your blood pressure and check for any neurologic symptoms after your DANYELZA infusion. Signs or symptoms of PRES may include:
    • severe headache
    • vision changes
    • changes in mental status, such as confusion, disorientation, or decreased alertness
    • difficulty speaking
    • weakness in your arms or legs
    • seizures
  • Numbness, tingling, or burning sensation in the arms or legs.
  • Nervous system problems of the eye. Signs or symptoms may include:
    • unequal pupil size
    • blurred vision
    • trouble focusing your eyes
    • larger pupil size (dilated)
    • decreased ability to see
    • sensitivity to light
  • Problems urinating or emptying your bladder (prolonged urinary retention).

Do not receive DANYELZA if you have had a severe allergic reaction to naxitamab-gqgk (the active ingredient in DANYELZA). Ask your healthcare provider if you are not sure.

Before receiving DANYELZA, tell your healthcare provider about all your medical conditions, including if you:

  • have high blood pressure
  • are pregnant or plan to become pregnant. DANYELZA may harm your unborn baby.
    • Your healthcare provider will do a pregnancy test before you start treatment with DANYELZA.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment and for 2 months after your last dose of DANYELZA. Talk to your healthcare provider about birth control choices that may be right for you during this time.
    • Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with DANYELZA.
  • are breastfeeding or plan to breastfeed. It is not known if DANYELZA passes into your breast milk. Do not breastfeed during treatment and for 2 months after your last dose of DANYELZA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of DANYELZA?
DANYELZA may cause serious side effects, including:

  • See “What is the most important information I should know about DANYELZA?”
  • High blood pressure (hypertension). High blood pressure is common in people who receive DANYELZA. Your blood pressure will be monitored during your DANYELZA infusion, and at least each day on Days 1 to 8 of each DANYELZA treatment cycle. Tell your healthcare provider right away if you get any signs or symptoms of high blood pressure, including:
    • headaches
    • seizures
    • nausea or vomiting
    • chest pain
    • dizziness
    • visual changes
    • shortness of breath
    • feeling that your heart is pounding or racing (palpitations)
    • nose bleeds

The most common side effects of DANYELZA include:

  • fast heart rate
  • vomiting
  • cough
  • nausea
  • decreased white blood cell, red blood cell, and platelet counts
  • diarrhea
  • decreased appetite
  • tiredness
  • skin rashes
  • decreased level of potassium, sodium, and phosphate in the blood
  • hives
  • fever
  • headache
  • injection site reaction
  • swelling of the body or only in one part of the body
  • anxiety
  • irritability
  • increased liver function blood tests
  • decreased blood sugar level
  • decreased calcium levels in the blood
  • decreased protein levels (albumin) in the blood

These are not all of the possible side effects of DANYELZA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please click for full Prescribing Information and Patient Information for DANYELZA including Boxed Warning on serious infusion-related reactions and nervous system problems, and talk to your doctor.